[Characteristics of the carriers of antibodies to hepatitis C virus with normal transaminases levels in HIV infected patients] NLM AIDSLINE Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


[Characteristics of the carriers of antibodies to hepatitis C virus with normal transaminases levels in HIV infected patients]

An Med Interna. 1998 Sep;15(9):459-63. Unique Identifier : AIDSLINE MED/99179252
Ramos Paesa C; Pascual Catalan A; Arazo Garces P; Aguirre Errasti JM; Hermida Lazcano I; Servicio de Medicina Interna, Hospital Miguel Servet, Zaragoza.

Abstract: BACKGROUND: To know the characteristics of the carriers of antibodies to hepatitis C virus (HCV) with persistently normal transaminases levels ("carriers") in coinfected with HIV, the incidence of the real viral activity and the factors that could determine it. PATIENTS AND METHODS: We analyzed 114 patients with criteria for chronic hepatitis C, 41 with detectable antibodies (anti-HCV), but without chemical evidence of a deteriorations of the liver function, all of them infected with HIV. In 6 patients was possible to determine the genotype of the HCV (INNO-LiPA HCV Innogenetics. Belgica) and in 32 the HCV-RNA (Amplicor HCV Roche Diagnostics). We compared the characteristics that could be differential between both groups, investigating the possible factors that could define the group of "carriers" with detectable viral activity. RESULTS: From the 32 "carriers" in which we could determine the HCV-RNA, 15 (46.8%) had a positive result. The incidence of women in the "carriers" group was higher (41.4% vs 22.8%) (p < 0.05). The serum levels of gammaglobulin (gr/dl) was higher in the chronic hepatitis group (2.23 +/- 0.6 vs 1.9 +/- 0.5) (p < 0.01); however, these levels were higher for the 15 patients RNA (-) patients (2.19 +/- 0.7 vs 1.66 +/- 0.41) (p < 0.01). The genotype distribution of HCV found in the "carriers" group with detectable viremia was: genotype 1(5 patients), subtype la (3 patients), subtype lb (2 patients) an genotype 3 (3 patients). There was no significant difference with respect to age, sex, degree of immunosuppression or the length of the infection with HCV. CONCLUSIONS: Approximately half of our "carriers" of anti-HCV without evidence of changes in the liver function, infected with HIV, show detectable viremia and so probably liver biopsy would be indicated. Women are more often "carriers" and the high levels of gammaglobulin could define the existence of a real viral activity.
Keywords: JOURNAL ARTICLE de la hepatitis C con transaminasas normales en infectados por el VIH. Adult Carrier State/*BLOOD/VIROLOGY English Abstract Female Hepatitis C Antibodies/BLOOD Hepatitis C-Like Viruses/ISOLATION & PURIF Hepatitis C, Chronic/BLOOD/*COMPLICATIONS Human HIV Infections/BLOOD/*COMPLICATIONS Liver Function Tests Male RNA, Viral/BLOOD Transaminases/BLOODKWDjournalarticledelahepatitisccontransaminasasnormaleseninfectadosporelvihKWDadultcarrierstate/KWDblood/virologyenglishabstractfemalehepatitiscantibodies/bloodhepatitisc-likeviruses/isolation&purifhepatitisc,chronic/blood/KWDcomplicationshumanhivinfections/blood/KWDcomplicationsliverfunctiontestsmalerna,viral/bloodtransaminases/blood
990630
A9961004

Copyright © 1999 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .